Dishman Carbogen subsidiary to co-invest more than CHF 15M with Japanese client to expand Swiss site

This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier.

Apr 29, 2021 11:04 IST India Infoline News Service

Dishman Pharmaceuticals
Dishman Carbogen Amcis Limited informed the exchanges Wednesday that the company’s subsidiary, Carbogen Amcis AG, pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a joint funding agreement with a longstanding Japan-based customer to build a site extension at the Bubendorf site in Switzerland.

The expansion will be created adjacent to an existing manufacturing facility on the Bubendorf Switzerland Site. This important expansion will incorporate a new production line comprising of two 850 L reactors and one agitated filter drier. The facility is designed for highly potent manufacturing up to category 4 (OEL of 1 µg/m³ and lower).

“We are grateful for the trust our customer has placed in us by deciding to support the Bubendorf site extension. Their investment will enable the creation of a state-of-the art facility that will benefit them directly,” said Pascal Villemagne, VP sales and Marketing, Carbogen Amcis.

“This joint investment cements our working relationship over the long term and lays the foundation for a promising future,” he added.

Carbogen Amcis will produce exclusively for the signatory customer a complex highly potent drug component for a commercial antibody-drug-conjugate API.

At around 11.20 am, Dishman Carbogen Amcis Ltd was trading at Rs157.55 per piece down Rs3.35 or 2.08% from its previous closing of Rs160.90 per piece on the BSE.

Related Story

Open Free Demat Account (Rs699)